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Background: Diabetics are known to have inferior outcomes following peripheral vascular interventions.
Thiazolidinediones are oral diabetic agents which improve outcomes following coronary bare metal stenting. No
studies have been performed evaluating thiazolidinedione use and outcomes following lower extremity endovascular
interventions. We hypothesize that diabetic patients taking thiazolidinediones at the time of primary superficial femoral
artery (SFA) stenting have fewer reinterventions.
Methods: A retrospective review was performed to identify diabetic patients undergoing primary SFA stenting. The
unit of analysis was the extremity. The primary outcome was freedom from target lesion revascularization stratified by
thiazolidinedione use, evaluated by Kaplan Meier curves and a log rank test. A Cox proportional hazards model was
constructed to determine variables associated with freedom from target lesion revascularization.
Results: SFA stents were placed in 138 extremities in 128 diabetic patients between August 1, 2001 and July 15, 2012.
Twenty-four patients were taking thiazolidinediones at the time of SFA stenting. All patients taking thiazolidinediones
had TASC A or B lesions. Twenty-seven extremities in the non-thiazolidinedione group had TASC C or D lesions and
were excluded to control for disease severity. Freedom from target lesion revascularization was significantly higher in
diabetics taking thiazolidinediones at 2 years, 88.5% vs. 59.4%, P = 0.02, SE < 10%. Cox modeling identified a protective
trend for thiazolidinedione use (thiazolidinedione use HR 0.33, 95% CI 0.09-1.13), whereas critical limb ischemia and
insulin use were associated with trends for worse freedom from target lesion revascularization.
Conclusions: This pilot, translation study demonstrates that diabetic patients taking thiazolidinediones at the time of
primary SFA stenting have decreased reintervention rates at 2 years. These results may be explained by higher
adiponectin levels or other anti-inflammatory effects in patients taking thiazolidinedione. National and regional quality
improvement registries should consider collecting information regarding specific diabetic regimens and use of PPAR
agonists such as cilostazol and fibrates.
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Figure 1 Cohort description. Cohort exclusion criteria are depicted.
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Superficial femoral artery (SFA) stenting has revolution-
ized the care provided to patients with lower extremity
peripheral artery disease and is a commonly performed
procedure [1]. Diabetes is a known risk factor for poor
clinical outcomes, such as recurrent claudication, de-
crease in ankle-brachial index or failure to heal a wound
[1-4]. Poor clinical outcomes following SFA stenting
frequently result in reintervention to correct in-stent re-
stenosis, narrowing of the stented arterial segment.
The reasons why diabetics are at increased risk for
developing in-stent restenosis are largely unknown. How-
ever, studying clinical outcomes associated with specific
medication regimens may prove useful. For example, prior
studies have identified that use of exogenous insulin is a
risk factor for restenosis following endovascular interven-
tion in the coronary and peripheral circulations [2,5,6].
Alternatively, use of thiazolidinediones (TZDs) has been
associated with decreased rates of in-stent restenosis for
coronary bare metal stents [7-9].
While the association between TZD use and outcomes
has been studied for patients undergoing coronary inter-
ventions, there is no data available for patients undergo-
ing interventions for low extremity peripheral arterial
disease. Therefore, we studied the association between
TZD use and reintervention rate for diabetic patients
undergoing SFA stenting. Our results demonstrate that
the rate of reintervention was significantly lower in dia-
betics taking TZDs versus diabetics not taking TZDs at
2 years, 88.5% vs. 59.4%, P = 0.02, SE < 10%.
Methods
We searched the vascular surgery database for elective
SFA stents between August 1, 2001 and August 15, 2012
[3]. The analysis includes only diabetics undergoing pri-
mary interventions. Diabetics who were not taking medi-
cations for glycemic control were excluded from our
analysis (n = 13) (Figure 1).
Diabetic patients were stratified by TZD use. Freedom
from target lesion revascularization (TLR) was evaluated.
After placement of an SFA stent, patients were evaluated
at 1, 6, and 12 months and then yearly. Recurrent symp-
toms, decreased ankle brachial index, or a stenosis iden-
tified by arterial duplex with greater than a 2.5× step-up
in peak systolic velocity prompted further investigation.
Patient demographics, comorbidities, and peripheral
arterial disease severity characteristics were analyzed
using Student’s t-test, chi square, and Fisher’s exact test.
Chronic kidney disease was defined as creatinine > 1.6.
Kaplan Meier survival curves using the peto method were
created to test for differences in freedom from TLR.
A Cox proportional hazards model was created to
identify predictors of freedom from TLR. Variables with
a P < 0.2 in univariate testing were included in a Coxproportional hazards model, and backwards stepwise elim-
ination was used to remove non-significant variables. The
statistical analysis was performed using STATA 12.1.
The Committee for the Protection of Human Subjects
at our institution granted institutional review board
approval for this study.
Results
Between August 1st 2001 and July 15th 2012, the vascu-
lar surgeons at our institution performed 363 primary
SFA stenting procedures. Of these, 128 diabetic patients
who were taking diabetic medications underwent SFA
stenting in 138 extremities (Figure 1). Demographics,
comorbidities, and cardiovascular medication use were
similar regardless of TZD use. Use of insulin, metformin,
and sulfonylureas were also similar. However, significant
differences related to disease severity variables were
present (Table 1). Specifically, all patients taking TZDs
had either a TASC A or B lesion and the prevalence
of critical limb ischemia (CLI) was significantly lower
among the TZD group. Technical success was achieved
in all cases. The mean stented vessel diameter was
5.4 mm (95% CI: 5.3-5.5 mm) for patients not taking
TZDs vs. 5.5 mm (95% CI: 5.2-5.8 mm) for patients taking
TZDs, p = 0.39. The mean stented length was 15.2 cm
(95% CI: 13.5-17.0 cm) for patients not taking TZDs vs.
8.9 cm (95% CI: 6.6-11.2 cm) for patients taking TZDs,
p < 0.01. Stents grafts were used in 2 cases; these patients







Age 64.46 69.57 0.06
Male 79.17% 54.39% 0.03
HTN 91.67% 88.60% 0.66
HLD 79.17% 81.58% 0.78
CAD 54.17% 54.39% 0.98
CKD 13.39% 14.91% 0.76
COPD 4.17% 11.93% 0.26
Current smoker 12.50% 22.81% 0.26
Statin 62.50% 69.03% 0.53
ASA 78.26% 79.44% 0.9
Plavix 39.13% 51.40% 0.29
Cilostazol 8.70% 14.02% 0.49
Insulin 50.00% 64.04% 0.24
Metformin 37.50% 35.09% 0.82
Sulfonylurea 29.17% 37.72% 0.49
CLI 33.33% 62.2/8% 0.01
TASC A or B 100% 76.32% 0.01
Preop toe pressure 52.5 40.95 0.18
3 Vessel outflow 41.67% 35.09% 0.54
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cantly higher for diabetics taking TZDs at 2 years, 88.5%
vs. 61.2%, p = 0.02 (Figure 2).
To address the concern that disease severity was dif-
ferent for those patients taking TZDs vs. those patients
not taking TZDs, we performed a second analysis lim-
ited to diabetic patients with TASC A and B lesionsFigure 2 Freedom from SFA Stent TLR among all diabetics by TZD use.
at the time of SFA stenting vs. 61.2% for those not taking a thiazolidinedione
standard error < 10% at all points on the graph.(Figure 1). This analysis excluded 27 patients with TASC
C and D lesions who were not taking TZDs; therefore,
87 patients not taking TZDs and 24 patients taking
TZDs were included in the cohort. Demographics,
comorbidities, use of cardiovascular medications, and
use of diabetic medications were similar for patients
with TASC A and B lesions regardless of TZD use.
However, the prevalence of CLI still remained lower
for patients taking TZDs (Table 2). The mean stented
vessel diameter was 5.4 mm (95% CI: 5.2-5.5 mm) for
patients not taking TZDs vs. 5.5 mm (95% CI: 5.2-
5.8 mm) for patients taking TZDs, p = 0.37. The mean
stented length was 12.7 cm (95% CI: 11.0-14.3 cm) for
patients not taking TZDs vs. 8.9 cm (95% CI: 6.6-
11.2 cm) for patients taking TZDs, p = 0.02. Despite
the exclusion of TASC C and D lesions, the association of
TZD use with improved freedom from TLR remained:
patients with a TASC A or B lesion taking a TZD at the
time of SFA stenting had a significantly better outcome
with 88.5% vs. 59.5% being free from TLR at 2 years,
P = 0.02 (Figure 3).
Finally, in our multivariable model, we found that
among all diabetic patients (n = 138), three variables were
associated with freedom from TLR: CLI, insulin use and
TZD use, with TZD use being protective (Table 3). How-
ever, the effect imparted by TZD use demonstrated only a
trend towards significance in this pilot study.
Discussion
The goal of this pilot, translational study was to identify
if TZD use is associated with improved TLR in diabetics
undergoing SFA stenting. This study is the first to show
that diabetics taking TZDs at the time of primary SFA
stenting have a lower reintervention rate within the firstFreedom from TLR was 88.5% for diabetics taking thiazolidinediones
at 2 years. This difference was statistically significant, p = 0.02, with a
Table 2 Characteristics of diabetic patients with TASC A






Age 64.45 68.75 0.11
Male 79.17% 55.17% 0.03
HTN 97.67% 88.51% 0.66
HLD 79.17% 81.61% 0.78
CAD 54.17% 54.02% 0.99
CKD 17.39% 16.09% 0.88
COPD 4.17% 8.54% 0.48
Current smoker 12.50% 18.39% 0.50
Statin 62.50% 70.93 0.43
ASA 78.26% 82.72% 0.63
Plavix 39.13% 44.44% 0.65
Cilostazol 8.70% 13.58% 0.53
Insulin 50.00% 68.97% 0.10
Metformin 37.50% 31.03% 0.62
Sulfonylurea 27.17% 31.03% 0.81
CLI 33.33% 60.92% 0.02
Preop toe pressure 52.5 43.46 0.32
3 vessel outflow 41.67% 37.21% 0.69
Table 3 Cox proportional hazards model
Hazard ratio Standard error P-value 95% CI
CLI 1.89 0.78 0.13 0.84-4.26
Insulin 1.87 0.81 0.15 0.79-4.39
TZD 0.33 0.21 0.08 0.09-1.13
Cox proportional hazards were performed to determine predictors of primary
patency. Critical limb ischemia (CLI), insulin use, thiazolidinediones (TZD) use
were identified as important variables.
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TZDs had reinterventions within the first year; the 2
reinterventions which were performed occurred between
12 and 18 months following the initial procedure.
Despite the mean stented length being slightly longer for
patients with TASC A and B lesions not taking TZDs
(12.7 cm vs 8.9 cm), this difference likely does not ex-
plain our result as it is clinically insignificant.Figure 3 Freedom from SFA Stent TLR among diabetics with TASC A
diabetics with TASC A or B lesions taking TZDs at the time of SFA stenting
statistically significant, P = 0.02, with a standard error < 10% at all points onAlthough our Cox proportional hazards model only
trended towards statistical significance, the model identi-
fied TZD use as a protective factor associated with im-
proved TLR, supporting our Kaplan Meier analysis. The
model also identified CLI and insulin use as predictors
of worse freedom from TLR which is consistent with
prior studies [2,3]. The main limitations of our model
were small cohort size and low number of failures. Des-
pite these limitations, this model is likely reliable and
should be tested in a larger cohort of patients.
The results from this study are consistent with data
from the cardiology literature demonstrating that TZD
use is protective against in-stent restenosis in the coron-
ary circulation among diabetic patients [7-9]. Surpris-
ingly, even when nondiabetic patients were randomized
to TZD use vs. placebo, TZD use resulted in decreased
in-stent restenosis following bare metal coronary stent-
ing [10]. One unexpected finding in our study was that
all diabetic patients taking TZDs appeared to have less
severe disease as exemplified by the presence of only
TASC A or B lesions and a lower prevalence of CLI as
an indication for stenting. Emerging data suggest that
TZD use may help modulate the development of ath-
erosclerosis. Review of the coronary artery disease lit-
erature identified preliminary data showing decreasedor B Lesions by TZD use. Freedom from TLR was 88.5% % for






















Figure 4 Proposed hypothesis–in-stent restenosis, diabetes,
thiazolidinedione use, adiponectin, and vascular smooth
muscle cell phenotype. The panel on the left proposes that diabetics
are at increased risk for in-stent restenosis due to lower adiponectin
levels increasing the likelihood that vascular smooth muscle cells
(VSMCs) will adopt the proliferative phenotype. The panel on the
right proposes that diabetics taking thiazolidinediones (TZDs) have
higher adiponectin levels increasing the likelihood that vascular
smooth muscle cells (VSMCs) will adopt the quiescent phenotype
which decreases the chance of developing in-stent restenosis.
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However, it is unknown if the same is true for lower
extremity atherosclerosis.
The mechanism through which TZDs protect against
in-stent restenosis is an area of active study. TZDs
are peroxisome proliferator-activatory receptor-gamma
(PPAR-gamma) agonists and have many effects: insulin
sensitization, anti-proliferation via blocking cell cycle
regulators, anti-platelet aggregation, and inhibition of
inflammatory cytokines such as tumor necrosis factor-
alpha [13-16]. TZDs also enhance anti-inflammatory pro-
teins such as adiponectin. Adiponectin is best known as
an insulin sensitizing adipokine secreted from adipocytes.
However, adiponectin is also secreted from VSMCs and
affects VSMC phenotype which has implications for the
development of in-stent restenosis [17].
VSMCs can exhibit two phenotypes: a proliferative
phenotype, and a quiescent or nonproliferative phenotype
[17]. In-stent restenosis develops after VSMCs adopt the
proliferative phenotype allowing cells to proliferate and
migrate inwards; this process is known as neointimal
hyperplasia. We have demonstrated that adiponectin
secretion by VSMCs promotes the nonproliferative pheno-
type of neighboring VSMCs in a paracrine manner [17].
Similarly, TZDs promote the nonproliferative VSMC
phenotype via adiponectin secretion [18-20]. The pro-
tective effect of adiponectin against neointimal hyper-
plasia has also been demonstrated in animal models.
Adiponectin knockout mice were shown to have in-
creased neointimal hyperplasia following femoral artery
wire injury versus wild type mice [21].
While specific mechanisms explaining the relationship
between diabetes and propensity for in-stent restenosis
have yet to be identified, the adiponectin pathway may
be important as diabetics are known to have lower
adiponectin levels than nondiabetics and higher rates of
in-stent restenosis [22,23]. We hypothesize that our
results are secondary to higher adiponectin levels in
patients taking TZDs (Figure 4). Support for this hy-
pothesis is derived from previous studies demonstrating
that low plasma adiponectin levels prospectively pre-
dicted in-stent restenosis for coronary bare metal stents
[24-27]. In order to test this hypothesis further, we are
currently enrolling patients in a prospective study de-
signed to examine the ability of pre-procedure adipo-
nectin levels to predict outcomes following lower
extremity stenting. If serum adiponectin level predicts
lower extremity in-stent restenosis, then a low adipo-
nectin level may be used to identify patients who
would benefit from treatment with a PPAR agonist,
such as cilostazol and fibrates [28,29].
Due to the retrospective nature of this study, several
limitations exist. First, it is unknown why some patients
were placed on TZDs and why others were not. The lowuse of TZDs may be due to changes in practice patterns
related to the FDA’s recent black box warning regarding
TZD use in patients with congestive heart failure [30].
Importantly, second generation TZDs are currently
under development and have been reported to have a
lower side effect profile [31]. Second, we were unable to
control for hemoglobin A1c level; many of our patients
receive primary care outside of our hospital system and
therefore hemoglobin A1c was not consistently recorded
in the medical record. Third, the study interval was rela-
tively long which may raise concerns regarding changes
in practice patterns. However, we evaluated TZD use
and found it to be consistent across the study interval
thereby decreasing this concern (data not shown).
Conclusions
This small pilot study suggests that TZD use is associ-
ated with decreased reinterventions following SFA stent-
ing in diabetic patients; this result should be investigated
further using larger databases. Higher adiponectin levels
resulting from PPAR-gamma activation secondary to
TZD use may be a potential explanation for our results.
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SFA stenting in order to measure adiponectin levels and
evaluate this hypothesis. Other anti-inflammatory effects
secondary to TZD use may also explain our results. We
would like to strongly encourage national and regional
quality improvement registries to collect information
regarding patient’s specific diabetic regimens and use of
PPAR agonists such as cilostazol and fibrates. Additional
epidemiological data will help us better understand how
to maximize medical management in diabetics under-
going endovascular intervention for peripheral arterial
disease.
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